Stefano Del Prato is a retired Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is affiliate Professor of Medicine at the Interdisciplinary Research Center “Health Science” of the Sant’Anna School of Advanced Studies in Pisa. He graduated MD cum laude from the University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.

Professor Del Prato’s research interests have always been concerned with diabetes and, in particular, the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome.

He is a member of many societies and associations, including the European Association for the Study of Diabetes (EASD), the American Diabetes Association, and the International Diabetes Federation. He acts as referee for all major journals and has served on the Editorial Boards for the Journal of Clinical Endocrinology and Metabolism, Diabetes Care, and the Journal of Diabetes and Its Complications, Journal of Endocrinological Investigation, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 articles in national and international journals and has been awarded several honours, including the Prize of the Italian Society of Diabetology for outstanding scientific activity. Having served as Vice-President of the EASD from 2011-14, he became President from 2020-2022. He also served as President of Italian Society of Diabetology (2012-14) and as Chairman of the European Foundation for the Study of Diabetes (2015-19) and is currently president of the European Diabetes Forum.

Duality of Interest: Professor Del Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria from Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Co, Menarini, Novo Nordisk and Sanofi. He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together with consultancy payments from Menarini.

Date: Autumn 2023